Fexapotide

Drug Profile

Fexapotide

Alternative Names: Fexapotide triflutate; NX-1207; REC-0482

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Nymox Pharmaceutical Corporation
  • Developer Nymox Pharmaceutical Corporation; Recordati
  • Class Antineoplastics; Proteins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Phase III Benign prostatic hyperplasia
  • Phase II Prostate cancer
  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 29 Nov 2016 Pooled efficacy data from three phase III trials in Benign prostatic hyperplasia released by Nymox Pharmaceutical
  • 11 Oct 2016 Efficacy data from long term extension study in Benign prostatic hyperplasia released by Nymox
  • 24 Aug 2016 Pooled efficacy data from two phase III, the US trials in benign prostatic hyperplasia released by Nymox Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top